Andrew L. Feldman MD

Andrew L. Feldman, M.D., studies the molecular pathogenesis of T-cell lymphomas, a group of malignant tumors of the immune system that are often fatal. The long-term goal of Dr. Feldman's research is to improve the lives of patients with T-cell lymphomas through individualized therapy in which a group of laboratory tests can predict — with high accuracy — the treatment most likely to be effective in an individual patient. To accomplish this, Dr. Feldman's team makes extensive use of next-generation sequencing technologies and innovative bioinformatic approaches to discover key genetic abnormalities in T-cell lymphomas.

The team then screens large numbers of T-cell lymphomas to determine whether such testing for these abnormalities can improve the diagnosis and subclassification of the tumors. In the laboratory, the biological consequences of the novel genetic abnormalities are tested to determine whether new drugs might be used to specifically target tumors with a given abnormality. Together, these findings can be translated to the clinic in the form of new laboratory tests that help select the right therapy for the right patient.